USPTO serial 78501419
TAGNOLOGIES
Reviewed by CopyMark Law Group
Status 601
- Filing date
- Status date
- Registration date
- —
- Examiner
- CHOINIERE, MONIQUE
- Law office
- TMEG LAW OFFICE 109 - EXAMINING ATTORNEY ASSIGNED
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TAGNOLOGIES?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Göttingen, DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Helen Hill Minsker
HELEN HILL MINSKER BANNER & WITCOFF LTD1001 G ST NW STE 1100WWASHINGTON, DC 20001-4597UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, in particular proteins including fusion proteins, in particular streptavidin and streptavidin muteins, antibodies, kinases, phosphatases, proteases, G proteins and G protein coupled receptors, peptides, in particular affinity peptides, peptides mediating cell membrane permeation as well as peptides mediating cell and tissue specifity, nucleic acids, in particular nucleic acids encoding the aforementioned proteins and peptides, vectors, in particular expression vectors as well as chemically synthesized oligonucleotides and nucleic acids, especially DNA, RNA, LNA, namely locked nucleic acid and PNA, namely peptide nucleic acid, oligonucleotides, oligonucleotides optionally furnished with an attached dye, viruses or viroids, cells, in particular body cells and cells of the immune system of mammals including human cells, combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells, kits for analysis comprised of resin for chromatographic separation of proteins and polypeptides and buffers for purification of proteins, kits for analysis comprised of a purification column packed with resin for chromatographic separation of proteins and polypeptides, and buffers for purification of proteins and polypeptides, kits for analysis comprised of a purification column packed with resin for chromatographic separation of protein and polypeptides, buffers for purification of proteins and polypeptides, and reagent for Western Blot detection of proteins, kits for analysis comprised of a purification column packed with resin for chromatographic separation of proteins and polypeptides, buffers for purification of proteins and polypeptides, reagent for Western Blot detection of proteins, an expression vector for recombinant production of proteins and polypeptides and reagent for inducing recombinant gene expression , and test agents, produced chemically and/or by means of gene technology for use in industry and science for purification and/or labeling and/or funcitionalization and/or detection and/or immobilization of nucleic acids, peptides and proteins including fusion proteins, viruses, viroids and/or cells, in particular of body cells and cells of the immune system of mammals including human cells, diagnostics, except for medical purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of immunological diseases, auto-immune diseases, viral diseases and cancer, and veterinary preparations, in particular nucleic acids, peptides and proteins including fusion proteins, viruses or viroids, cells, in particular body cells and cells of the immune system of mammals including human cells, furthermore chemically and/or by means of gene technology produced combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells, diagnostics for medical purposes as well as antisera and vaccines | ACTIVE | — |
| 042 | Research in science and industry in the areas of biochemistry, diagnostics and pharmaceuticals, services of an analytical, biochemical or pharmaceutical laboratory, in particular synthesis and purification of peptides and proteins, purification of viruses and viroids, cultivation and purification of cells, in particular of body cells and cells of the immune system of mammals including human cells, synthesis of nucleic acids and oligonucleotides, synthesis of vectors, in particular of expression vectors, preparation of combination products of proteins and/or peptides and other proteins or peptides or nucleic acids or viruses or viroids or cells by chemical means and/or means of gene technology, synthesis of active pharmaceutical agents as well as isolation of antisera and vaccines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 23, 2007 | MAB1 | ABANDONMENT NOTICE MAILED - EXPRESS ABANDONMENT | — |
| Jan 23, 2007 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Jan 23, 2007 | EXAR | TEAS EXPRESS ABANDONMENT RECEIVED | — |
| Oct 6, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 23, 2006 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jul 23, 2006 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Jun 16, 2006 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Dec 14, 2005 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Dec 14, 2005 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Dec 5, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Nov 17, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 17, 2005 | PAPER RECEIVED | — | |
| May 25, 2005 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 25, 2005 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 19, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 26, 2004 | NWAP | NEW APPLICATION ENTERED | — |